CAJ | 학술논문

对甲状腺功能亢进症(甲亢)及甲亢性心脏病(甲亢心)患者进行脑钠肽检测.甲亢心患者血浆脑钠肽浓度高于甲亢与健康对照者,分别为(433±141)μg/L,(110±38)μg/L和(10±3)μg/L(P均<0.01).甲亢患者治疗3个月后,脑钠肽浓度显著下降(42±36)μg/L(P<0.01);9例(32%)高脑钠肽患者发生甲亢心,低脑钠肽者无甲亢心发生(P<0.05).在评价甲亢预后与甲亢治疗反应中脑钠肽具有重要的应用价值.
대갑상선공능항진증(갑항)급갑항성심장병(갑항심)환자진행뇌납태검측.갑항심환자혈장뇌납태농도고우갑항여건강대조자,분별위(433±141)μg/L,(110±38)μg/L화(10±3)μg/L(P균<0.01).갑항환자치료3개월후,뇌납태농도현저하강(42±36)μg/L(P<0.01);9례(32%)고뇌납태환자발생갑항심,저뇌납태자무갑항심발생(P<0.05).재평개갑항예후여갑항치료반응중뇌납태구유중요적응용개치.
Twenty-two patients with hyperthyroid caxdiopathy(HTC),38 patients with hyperthyroid (HT),and 10 healthy controls were tested for plasma levels of brain natriuretic peptide(BNP).The findings showed that BNP level in HTC group(433±141)μg/L was significantly higher than that in HT group(110±38)μg/L and healthy control group(10±3)μg/L(both P<0.01);HT group vs healthy control group,P<0.01).After 3 months'treatment for HT,BNP decreased significantly.The patients with higher BNP levels had an increased incidence of HTC.Plasma BNP test might be useful in predicting the prognosis and the treatment efficacy in patients with HT.